Thursday

28th Mar 2024

Vaccine selfishness goes against science, EU regulator warns

  • Guido Rasi, the EMA director, was professor of microbiology at the University of Rome (Photo: eu2018.at)

People most in need, not national hoarders, should get the first shots of any future coronavirus vaccine, the EU medicines regulator has said.

The first batches should go to "people most at risk of infection", such as medical staff on the front lines or transport sector workers, not just in all EU countries, but internationally, Guido Rasi, who heads the European Medicines Agency (EMA) in Amsterdam, said on Monday (18 May).

Read and decide

Join EUobserver today

Get the EU news that really matters

Instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

That would create a "first ring of protection", which could later be fanned out to other groups as vaccine stocks grew, he said.

Scientists would have to model details of which "communities" to immunise first, but the ring method was "the rational approach", Rasi added.

The EMA authorises medicines for EU-wide distribution.

Rasi, who used to be professor of microbiology at the University of Rome, spoke to MEPs on the European Parliament's health committee in a videoconference.

But despite the EMA's good services, vaccine production and distribution will be decided at national and corporate level in Europe and beyond.

There is no coronavirus vaccine yet.

But "we [countries] shouldn't fight each other. We should make it [a vaccine] available community-wise, not country-wise ... I feel strongly about this," Rasi said.

The European Commission and EMA were working on "joint procurement" of vaccines, he noted.

The EMA was also working on "compassionate use" authorisation, a special fast-track procedure, of Remdesivir.

The drug, developed by Irish company Gilead Sciences Ireland, has helped patients suffering from the Sars and Ebola viruses in the past.

The emergency EMA approval could be given "in the coming days", Rasi said.

Research on monoclonal antibodies was promising, he added, but he "didn't see anything" other than Remdesivir on the approval horizon.

Monoclonal antibodies are human proteins used by the immune system, which can be engineered by bio-tech firms to attack specific targets, such as coronavirus.

A coronavirus vaccine could be a goldmine for companies such as British and French pharmaceutical giants GlaxoSmithKline and Sanofi, who recently joined forces to create one.

And the EMA was being bombarded with new pitches by drugs firms, the agency's director noted.

It was a good idea to develop multiple vaccines at the same time, in order to increase availability and treatment options, Rasi said.

Some vaccines worked better in some demographics than others, the EU expert noted, and science never created panaceas that immunised 100 percent of patients with zero adverse reactions, he said.

EMA staff were "passionate" about stopping the pandemic, Rasi said.

The EMA had paused some publications because of the disruption caused by moving from London to the Netherlands after Brexit, he noted.

But it would be publishing all its research on corona-vaccines, he promised.

Vaccine sceptics

The good news was, the longer the virus stayed, the better the vaccines would become, Rasi said.

The bad news was it might not go away, like hepatitis or HIV, he added.

More bad news was that vaccine scepticism, popular fears about vaccine side-effects and conspiracy theories, could have a "very important negative effect" on the fight to stop coronavirus, Rasi said.

People should still take normal flu vaccines, not least so that doctors knew whether patients had flu or coronavirus, he said.

And as governments and industries pondered the long-term effect of events, Rasi, the EMA head, advised EU capitals to further integrate health policy.

Vaccine-production should also be brought closer to home, he added, in terms of Europe's medical security.

"Making vaccines in a third country gives us some vulnerability. Some 10 years ago we enjoyed a local capacity in Europe, but now it has been almost dismantled," he said.

"That's an overall pharmaceutical policy that Europe will have to consider," Rasi said.

Agenda

EU vaccine fundraising kicks off This WEEK

Worldwide efforts will be made to find €7.5bn for a possible cure for Covid-19. The commission will also flesh out its estimates of the coming recession.

EU launches funding drive for Covid-19 vaccine

The European Commission launches on Monday an initiative to raise €7.5bn to speed up the development of vaccines, treatment and testing capacity, ensuring that is equally "available to everyone and at affordable prices" and avoiding nationalisms.

EU wants to pay in advance for promising vaccines

EU health ministers will discuss on Friday plans to have the Commission negotiate with pharmaceutical companies on behalf of EU countries, make advaced payments and secure enough vaccines for Europeans.

Commission plans strategy to 'maximise' vaccine access

The EU Commission plans a vaccine stategy to make sure all citizens have access to it once it is ready, while it is also seeking to negotiate with pharmaceutical companies on securing the vaccine.

EU commisisoner Šuica sounds alarm on demographic shift

The EU will have to step up its efforts to tackle looming demographic challenges over the next five years. If not, the bloc faces "sleepwalking into dark scenarios", warns EU commission vice-president Dubravka Šuica.

Latest News

  1. German bank freezes account of Jewish peace group
  2. EU Modernisation Fund: an open door for fossil gas in Romania
  3. 'Swiftly dial back' interest rates, ECB told
  4. Moscow's terror attack, security and Gaza
  5. Why UK-EU defence and security deal may be difficult
  6. EU unveils plan to create a European cross-border degree
  7. How migrants risk becoming drug addicts along Balkan route
  8. 2024: A Space Odyssey — why the galaxy needs regulating

Stakeholders' Highlights

  1. Nordic Council of MinistersJoin the Nordic Food Systems Takeover at COP28
  2. Nordic Council of MinistersHow women and men are affected differently by climate policy
  3. Nordic Council of MinistersArtist Jessie Kleemann at Nordic pavilion during UN climate summit COP28
  4. Nordic Council of MinistersCOP28: Gathering Nordic and global experts to put food and health on the agenda
  5. Friedrich Naumann FoundationPoems of Liberty – Call for Submission “Human Rights in Inhume War”: 250€ honorary fee for selected poems
  6. World BankWorld Bank report: How to create a future where the rewards of technology benefit all levels of society?

Stakeholders' Highlights

  1. Georgia Ministry of Foreign AffairsThis autumn Europalia arts festival is all about GEORGIA!
  2. UNOPSFostering health system resilience in fragile and conflict-affected countries
  3. European Citizen's InitiativeThe European Commission launches the ‘ImagineEU’ competition for secondary school students in the EU.
  4. Nordic Council of MinistersThe Nordic Region is stepping up its efforts to reduce food waste
  5. UNOPSUNOPS begins works under EU-funded project to repair schools in Ukraine
  6. Georgia Ministry of Foreign AffairsGeorgia effectively prevents sanctions evasion against Russia – confirm EU, UK, USA

Join EUobserver

EU news that matters

Join us